Jemperli plus Zejula combo significantly improved progression-free survival in primary advanced or recurrent endometrial cancer: GSK

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said, “Patients with MMRp/MSS primary advanced or recurrent endometrial cancer have few approved treatment options. The positive topline results reinforce our approach of building combination therapies with dostarlimab as the backbone in an effort to improve patient outcomes and options.”

Analysis of the full trial data, including the key secondary endpoint of overall survival (OS), is ongoing. OS data is immature and will continue to be followed.

The safety profile of dostarlimab plus carboplatin and paclitaxel, followed by dostarlimab plus niraparib, was generally consistent with the known safety profiles of the individual agents.

Full results from this analysis will be presented at an upcoming scientific meeting, published in a medical journal, and shared with regulatory authorities.